Inhibikase Therapeutics Inc (IKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $213.21M
Last updated: Nov 17, 2026 at 4:30 PM ET
Inhibikase Therapeutics Inc (IKT) Statistics
Inhibikase Therapeutics (IKT) has a market cap of $213.21M and an enterprise value of $161.51M. Its share count is up 118.70% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 24.25% below the market cap, as cash exceeds debt.
| Market Cap | $213.21M |
|---|---|
| Enterprise Value | $161.51M |
| Latest price (Nov 17, 2026) | $1.38 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 9.80% over 52 weeks and trades 25.41% below its 50-day average.
| Beta (1Y) | 1.66 |
|---|---|
| 52-Week Change | -9.80% |
| 1-Month Change | -16.11% |
| 3-Month Change | -43.67% |
| 6-Month Change | -12.10% |
| 5-Year Change | -87.02% |
| Total Return (1Y) | -9.80% |
| Total Return (5Y CAGR) | -34.40% |
| Return vs SPY (1Y) | -25.31% |
| Max Drawdown (1Y) | -45.24% |
| Max Drawdown (3Y) | -65.24% |
| Sharpe Ratio (1Y) | -0.24 |
| Correlation with SPY (1Y) | 0.36 |
| 50-Day Average | $1.85 |
| 200-Day Average | $1.93 |
| 52-Week Range | $1.40 to $2.61 |
| RSI (14 Days) | 36.4 |
| Average Volume (20 Days) | 573.10K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 15.34x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 15.34x |
|---|---|
| Quick Ratio | 15.34x |
| Debt / Equity | 0.00x |
| Interest Coverage | 13.09x |
Returns and Efficiency
Return on equity is -36.64% over the last 12 months, against a 5-year average of -70.92%.
| Return on Equity (ROE) | -36.64% |
|---|---|
| Return on Assets (ROA) | -34.29% |
| ROE (5Y Average) | -70.92% |
| ROA (5Y Average) | -58.59% |
| ROIC (5Y Average) | -23.75% |
Scores
IKT has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$36.81K |
| Operating Income | -$74.90M |
| Pretax Income | -$69.21M |
| Net Income | -$69.17M |
| Reported EPS (TTM) | -$0.40 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 93.58% of the $201.75M in total assets.
| Cash and Equivalents | $51.70M |
|---|---|
| Total Debt | $0 |
| Net Cash | $51.70M |
| Net Cash Per Share | $0.26 |
| Working Capital | $185.78M |
| Shareholder Equity | $188.80M |
| Book Value Per Share | $0.96 |
| Total Assets | $201.75M |
| Total Liabilities | $12.96M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$49.37M |
|---|---|
| FCF Per Share | -$0.36 |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -0.45% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -0.45% |
Dividends and Yields
IKT does not pay a dividend.
| Buyback Yield | -58.74% |
|---|---|
| Shareholder Yield | -58.74% |
Stock Splits
The last split was a 1-for-6 reverse split on Jun 30, 2023.
| Last Split Date | Jun 30, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:6 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About IKT
What is IKT's market cap?
Inhibikase Therapeutics has a market cap of $213.21M. Its enterprise value, which adds debt and subtracts cash, is $161.51M.
How many shares of IKT are outstanding?
Inhibikase Therapeutics has 196.94M shares outstanding. The count is up 118.70% from a year earlier.
Does IKT pay a dividend?
No. Inhibikase Therapeutics does not pay a dividend.
How much debt does IKT have?
Inhibikase Therapeutics has $0 of total debt and $51.70M of cash and equivalents, a net cash position of $51.70M.
IKT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors